132 related articles for article (PubMed ID: 1960329)
1. Safety and efficacy of a new regimen of intravenous recombinant tissue-type plasminogen activator potentially suitable for either prehospital or in-hospital administration.
McKendall GR; Attubato MJ; Drew TM; Feit F; Sharaf BL; Thomas ES; Teichman S; McDonald MJ; Williams DO
J Am Coll Cardiol; 1991 Dec; 18(7):1774-8. PubMed ID: 1960329
[TBL] [Abstract][Full Text] [Related]
2. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
[TBL] [Abstract][Full Text] [Related]
3. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator.
Neuhaus KL; Feuerer W; Jeep-Tebbe S; Niederer W; Vogt A; Tebbe U
J Am Coll Cardiol; 1989 Nov; 14(6):1566-9. PubMed ID: 2509531
[TBL] [Abstract][Full Text] [Related]
4. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS).
Neuhaus KL; von Essen R; Tebbe U; Vogt A; Roth M; Riess M; Niederer W; Forycki F; Wirtzfeld A; Maeurer W
J Am Coll Cardiol; 1992 Apr; 19(5):885-91. PubMed ID: 1552106
[TBL] [Abstract][Full Text] [Related]
5. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
Arnold AE; Brower RW; Collen D; van Es GA; Lubsen J; Serruys PW; Simoons ML; Verstraete M
J Am Coll Cardiol; 1989 Sep; 14(3):581-8. PubMed ID: 2504798
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction.
Purvis JA; McNeill AJ; Siddiqui RA; Roberts MJ; McClements BM; McEneaney D; Campbell NP; Khan MM; Webb SW; Wilson CM
J Am Coll Cardiol; 1994 Jan; 23(1):6-10. PubMed ID: 8277097
[TBL] [Abstract][Full Text] [Related]
7. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
[TBL] [Abstract][Full Text] [Related]
8. Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. RAAMI Study Investigators.
Carney RJ; Murphy GA; Brandt TR; Daley PJ; Pickering E; White HJ; McDonough TJ; Vermilya SK; Teichman SL
J Am Coll Cardiol; 1992 Jul; 20(1):17-23. PubMed ID: 1607520
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of a single intravenous bolus injection of tissue-type plasminogen activator in acute myocardial infarction. Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST) Investigators.
Hackett D; Andreotti F; Haider AW; Brunelli C; Shahi M; Fussell A; Buller N; Foale R; Lipkin D; Caponnetto S
Am J Cardiol; 1992 Jun; 69(17):1393-8. PubMed ID: 1590225
[TBL] [Abstract][Full Text] [Related]
10. A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. KAMIT Study Group.
Grines CL; Nissen SE; Booth DC; Branco MC; Gurley JC; Bennett KA; DeMaria AN
J Am Coll Cardiol; 1989 Sep; 14(3):573-80. PubMed ID: 2504797
[TBL] [Abstract][Full Text] [Related]
11. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
[TBL] [Abstract][Full Text] [Related]
12. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
Arnout J; Simoons M; de Bono D; Rapold HJ; Collen D; Verstraete M
J Am Coll Cardiol; 1992 Sep; 20(3):513-9. PubMed ID: 1512327
[TBL] [Abstract][Full Text] [Related]
13. Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group.
Wall TC; Califf RM; George BS; Ellis SG; Samaha JK; Kereiakes DJ; Worley SJ; Sigmon K; Topol EJ
J Am Coll Cardiol; 1992 Mar; 19(3):482-9. PubMed ID: 1537998
[TBL] [Abstract][Full Text] [Related]
14. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial.
Brener SJ; Zeymer U; Adgey AA; Vrobel TR; Ellis SG; Neuhaus KL; Juran N; Ivanc TB; Ohman EM; Strony J; Kitt M; Topol EJ
J Am Coll Cardiol; 2002 Feb; 39(3):377-86. PubMed ID: 11823073
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction.
Magnani B
J Am Coll Cardiol; 1989 Jan; 13(1):19-26. PubMed ID: 2491867
[TBL] [Abstract][Full Text] [Related]
16. Dose-ranging study with a new two-chain rt-PA in patients with acute myocardial infarction: a multicenter trial.
DeWood MA; Kurnik PB; Jolly MK; Jain AC; Khaja F; Gorfinkel HJ; Morris DL; Satler L; LittleJohn J
Clin Cardiol; 1993 Apr; 16(4):302-10. PubMed ID: 8458110
[TBL] [Abstract][Full Text] [Related]
17. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).
Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
J Am Coll Cardiol; 1988 Sep; 12(3):581-7. PubMed ID: 3042835
[TBL] [Abstract][Full Text] [Related]
18. HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte.
von Essen R; Zeymer U; Tebbe U; Jessel A; Kwasny H; Mateblowski M; Niederer W; Wagner J; Mäurer W; von Leitner ER; Haerten K; Roth M; Neuhaus KL
Coron Artery Dis; 1998; 9(5):265-72. PubMed ID: 9710686
[TBL] [Abstract][Full Text] [Related]
19. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
Kirshenbaum JM; Bahr RD; Flaherty JT; Gurewich V; Levine HJ; Loscalzo J; Schumacher RR; Topol EJ; Wahr DW; Braunwald E
Am J Cardiol; 1991 Dec; 68(17):1564-9. PubMed ID: 1746455
[TBL] [Abstract][Full Text] [Related]
20. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial.
Williams DO; Borer J; Braunwald E; Chesebro JH; Cohen LS; Dalen J; Dodge HT; Francis CK; Knatterud G; Ludbrook P
Circulation; 1986 Feb; 73(2):338-46. PubMed ID: 3080261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
